Gyrodyne , LLC (NASDAQ:GYRO – Get Free Report) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 1,295 shares, an increase of 257.7% from the July 30th total of 362 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,475 shares, the short-interest ratio is presently 0.9 days.
Institutional Investors Weigh In On Gyrodyne
A hedge fund recently bought a new position in Gyrodyne stock. Susquehanna International Group LLP bought a new position in Gyrodyne , LLC (NASDAQ:GYRO – Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 14,186 shares of the real estate investment trust’s stock, valued at approximately $142,000. Susquehanna International Group LLP owned 0.65% of Gyrodyne as of its most recent SEC filing. 71.36% of the stock is currently owned by institutional investors.
Gyrodyne Stock Up 1.2%
GYRO traded up $0.06 during midday trading on Friday, hitting $5.25. The stock had a trading volume of 1,636 shares, compared to its average volume of 2,418. Gyrodyne has a 1 year low of $5.19 and a 1 year high of $11.00. The business has a fifty day moving average of $5.74 and a 200 day moving average of $7.05.
Gyrodyne Company Profile
Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.
The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.
See Also
- Five stocks we like better than Gyrodyne
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Gyrodyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyrodyne and related companies with MarketBeat.com's FREE daily email newsletter.
